CN110090222A - 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 - Google Patents
一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 Download PDFInfo
- Publication number
- CN110090222A CN110090222A CN201910075748.0A CN201910075748A CN110090222A CN 110090222 A CN110090222 A CN 110090222A CN 201910075748 A CN201910075748 A CN 201910075748A CN 110090222 A CN110090222 A CN 110090222A
- Authority
- CN
- China
- Prior art keywords
- mastitis
- injection
- milk
- anemoside
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 229940079593 drug Drugs 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 230000003612 virological effect Effects 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 title description 8
- 239000009806 pulsatillae Substances 0.000 title description 5
- 210000004080 milk Anatomy 0.000 claims abstract description 149
- 235000013336 milk Nutrition 0.000 claims abstract description 148
- 239000008267 milk Substances 0.000 claims abstract description 148
- 241000283690 Bos taurus Species 0.000 claims abstract description 127
- 208000004396 mastitis Diseases 0.000 claims abstract description 127
- OUHBKBTZUPLIIA-OTEDBJMHSA-N [(2s,3r,4s,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1r,3as,5ar,5br,7ar,8r,9s,11ar,11br,13ar,13br)-9-[(2s,3r,4s,5s)-4,5-dihydroxy- Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@H]([C@@H](CC3)C(C)=C)[C@@H]3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC3)(C)CC4)O2)O)[C@H](O)[C@H]1O OUHBKBTZUPLIIA-OTEDBJMHSA-N 0.000 claims abstract description 84
- YHBNVRGUYZBJJF-UHFFFAOYSA-N Anemoside B4 Natural products CC1OC(OC2C(O)C(O)C(OCC3OC(OC(=O)C4CC(C5C4CCC6(C)C5CCC7C8(C)CCC(OC9OCC(O)C(O)C9OC%10OC(C)C(O)C(O)C%10O)C(C)(CO)C8CCC67C)C(=C)C)C(O)C(O)C3O)OC2CO)C(O)C(O)C1O YHBNVRGUYZBJJF-UHFFFAOYSA-N 0.000 claims abstract description 82
- OUHBKBTZUPLIIA-UHFFFAOYSA-N pulchinenoside B Natural products OC1C(O)C(O)C(C)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(OC(=O)C34C(C(CC3)C(C)=C)C3C(C5(C)CCC6C(C)(CO)C(OC7C(C(O)C(O)CO7)OC7C(C(O)C(O)C(C)O7)O)CCC6(C)C5CC3)(C)CC4)O2)O)C(O)C1O OUHBKBTZUPLIIA-UHFFFAOYSA-N 0.000 claims abstract description 82
- 238000002347 injection Methods 0.000 claims abstract description 74
- 239000007924 injection Substances 0.000 claims abstract description 74
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000000470 constituent Substances 0.000 claims abstract description 6
- 210000000481 breast Anatomy 0.000 claims description 45
- 239000006071 cream Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 206010059866 Drug resistance Diseases 0.000 abstract description 14
- 241001504477 Pycnonotidae Species 0.000 abstract description 11
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 229930191447 pulchinenoside Natural products 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 35
- 208000024891 symptom Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 210000003128 head Anatomy 0.000 description 11
- 238000010255 intramuscular injection Methods 0.000 description 11
- 239000007927 intramuscular injection Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000013558 reference substance Substances 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000020247 cow milk Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- KYOHRXSGUROPGY-OFNLCGNNSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical compound OS(O)(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 KYOHRXSGUROPGY-OFNLCGNNSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 241000123887 Pulsatilla chinensis Species 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229950009592 cefquinome Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960000740 enrofloxacin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006262 Breast inflammation Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000006650 Overbite Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018100972213 | 2018-01-31 | ||
CN201810097221 | 2018-01-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110090222A true CN110090222A (zh) | 2019-08-06 |
CN110090222B CN110090222B (zh) | 2022-04-05 |
Family
ID=67443779
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910074964.3A Active CN110090221B (zh) | 2018-01-31 | 2019-01-25 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
CN201910075748.0A Active CN110090222B (zh) | 2018-01-31 | 2019-01-25 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910074964.3A Active CN110090221B (zh) | 2018-01-31 | 2019-01-25 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
Country Status (12)
Country | Link |
---|---|
US (3) | US11510933B2 (zh) |
EP (2) | EP3747445B1 (zh) |
JP (1) | JP7021360B2 (zh) |
CN (2) | CN110090221B (zh) |
AU (2) | AU2019214081B2 (zh) |
BR (2) | BR112020015536A2 (zh) |
CA (2) | CA3089522C (zh) |
ES (1) | ES2964618T3 (zh) |
MX (1) | MX2020008047A (zh) |
PL (1) | PL3747445T3 (zh) |
UA (1) | UA127576C2 (zh) |
WO (2) | WO2019149155A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110090221A (zh) * | 2018-01-31 | 2019-08-06 | 四川英路维特医药科技有限公司 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
CN111249289A (zh) * | 2020-02-14 | 2020-06-09 | 广西英路维特药物有限公司 | 一种消炎和/或抗过敏的口腔护理产品或药品 |
CN113633682A (zh) * | 2021-07-22 | 2021-11-12 | 广西馨海药业科技有限公司 | 一种治疗带状疱疹的乳膏剂及其制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111228280B (zh) * | 2020-01-17 | 2021-08-13 | 陕西科技大学 | 白头翁皂苷a3在抑制多重耐药雷氏普罗威登斯菌生长中的应用 |
CN111249291B (zh) * | 2020-03-19 | 2023-07-18 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗/预防细菌性肺炎药物的用途 |
CN114159453A (zh) * | 2021-12-24 | 2022-03-11 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗或预防银屑病的药物的用途 |
CN114533748B (zh) * | 2022-02-15 | 2023-11-28 | 广西馨海药业科技有限公司 | 白头翁皂苷b4在制备治疗或预防子宫肌瘤的药物的用途 |
CN119679056A (zh) * | 2025-02-27 | 2025-03-25 | 金华职业技术大学 | 一种用于防治猪细小病毒病的饲料及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102234305A (zh) * | 2011-05-06 | 2011-11-09 | 南京泽朗医药科技有限公司 | 一种制备高纯度白头翁皂苷b4的方法 |
CN102898496A (zh) * | 2012-10-12 | 2013-01-30 | 苏州世林医药技术发展有限公司 | 一种齐墩果酸型皂苷的制备方法 |
AU2014227506A1 (en) * | 2008-12-04 | 2014-10-09 | Boehringer Ingelheim Animal Health USA Inc. | Intramammary teat sealant |
CN105213410A (zh) * | 2015-10-20 | 2016-01-06 | 刘琦 | 白头翁皂苷b4作为免疫调节剂在治疗急性炎症药物中的应用 |
CN105535004A (zh) * | 2016-02-02 | 2016-05-04 | 刘琦 | 白头翁皂苷b4作为ev71病毒抑制剂在制备抗手足口病药物中的应用 |
CN107029040A (zh) * | 2017-05-02 | 2017-08-11 | 湖南农业大学 | 治疗奶牛隐性乳房炎的复方中药散剂 |
CN110090221A (zh) * | 2018-01-31 | 2019-08-06 | 四川英路维特医药科技有限公司 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5156394B2 (ja) * | 2005-02-03 | 2013-03-06 | エスケー ケミカルズ カンパニー リミテッド | 脳機能改善効果を有するオキナグサ抽出物 |
CN101337033A (zh) * | 2007-07-08 | 2009-01-07 | 宫兆荣 | 抗犬细小病毒制剂 |
CN101411762A (zh) * | 2007-10-19 | 2009-04-22 | 天津生机集团有限公司 | 治疗犬细小病毒病的中药组合物及其制备方法 |
CN101537059B (zh) * | 2009-04-20 | 2011-05-25 | 西南大学 | 抗肠炎型犬细小病毒病的中药组合物及其制备方法和应用 |
CN101564524B (zh) * | 2009-06-05 | 2011-03-16 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种治疗犬细小病毒病的中药注射剂及其制备方法 |
CN101670026A (zh) * | 2009-08-28 | 2010-03-17 | 天津生机集团股份有限公司 | 一种治疗犬细小病毒病的中西药组合物及其制备方法 |
CN101695550A (zh) * | 2009-10-29 | 2010-04-21 | 扬中牧乐药业有限公司 | 一种用于肠炎型犬细小病毒病辅助治疗的纯中药制剂及其制备方法 |
CN102100826A (zh) * | 2009-12-16 | 2011-06-22 | 青岛康地恩药业有限公司 | 一种治疗犬细小病毒性肠炎的中药复方制剂及其制备方法 |
CN101732517B (zh) * | 2009-12-30 | 2012-03-28 | 东北农业大学 | 一种治疗犬瘟热的中药组合物及其制备方法 |
CN101926861A (zh) * | 2010-08-31 | 2010-12-29 | 四川华神农大动物保健药品有限公司 | 用于增强非特异性免疫功能的中药兽用药的制备方法 |
CN102077915A (zh) * | 2010-09-19 | 2011-06-01 | 周剑峰 | 防治猪细小病毒感染的饲料添加剂 |
CN102100753B (zh) * | 2011-03-05 | 2012-07-04 | 中国农业科学院兰州畜牧与兽药研究所 | 治疗奶牛子宫内膜炎的药物 |
CN102397532B (zh) * | 2011-11-16 | 2013-05-22 | 青岛绿曼生物工程有限公司 | 一种治疗雏番鸭细小病毒病的复方蜂胶组合物及其制备方法 |
CN102512547B (zh) * | 2011-12-14 | 2013-06-26 | 北安市飞龙动物药厂 | 一种治疗犬瘟热病毒的中药组合物及其制备方法 |
CN103656116A (zh) * | 2012-09-20 | 2014-03-26 | 张波 | 一种治疗犬瘟热的中药药方的制备方法 |
CN103405666B (zh) * | 2013-07-25 | 2015-04-15 | 天津集合科技有限公司 | 一种治疗犬瘟热的中药组合物及其制备方法 |
CN103948876B (zh) * | 2014-05-14 | 2015-04-15 | 深圳市红瑞生物科技有限公司 | 治疗细小病毒的药物及其制备方法 |
CN104083564A (zh) * | 2014-06-20 | 2014-10-08 | 钟云仙 | 一种利用假友水龙骨治疗动物腐蹄病的中药 |
CN104161871B (zh) * | 2014-08-06 | 2016-04-27 | 新乡医学院 | 白秃疮(白癣)外用搓涂酒剂及其制备方法 |
KR102213617B1 (ko) | 2014-08-12 | 2021-02-05 | 주식회사 엘지생활건강 | 풀키네노시드 b4를 포함하는 피부 미백 또는 항염증용 화장료 또는 약학 조성물 |
CN106860844A (zh) * | 2015-12-10 | 2017-06-20 | 重庆英华农业开发有限公司 | 用于犬类细小病毒感染症的纯中药配方 |
CN106039074A (zh) * | 2016-07-12 | 2016-10-26 | 张绪伟 | 治疗犬细小病毒的药片 |
CN107137413B (zh) | 2017-06-21 | 2020-07-14 | 苏州大学 | 白头翁皂苷b4在制备治疗疼痛的药物中的应用 |
CN108938654B (zh) | 2017-07-07 | 2021-06-08 | 刘琦 | 一种白头翁皂苷b4的注射用制剂 |
EP3650009A4 (en) * | 2017-07-07 | 2020-12-30 | Qi Liu | PULSATILLA SAPONIN B4 PREPARATION FOR INJECTION |
CN107441086A (zh) * | 2017-07-27 | 2017-12-08 | 哈尔滨珍宝制药有限公司 | 一种药物组合物及其制备方法和用途 |
-
2019
- 2019-01-25 PL PL19746721.0T patent/PL3747445T3/pl unknown
- 2019-01-25 UA UAA202005100A patent/UA127576C2/uk unknown
- 2019-01-25 CA CA3089522A patent/CA3089522C/en active Active
- 2019-01-25 BR BR112020015536-5A patent/BR112020015536A2/pt unknown
- 2019-01-25 EP EP19746721.0A patent/EP3747445B1/en active Active
- 2019-01-25 WO PCT/CN2019/073238 patent/WO2019149155A1/zh active Application Filing
- 2019-01-25 EP EP19747611.2A patent/EP3747446B1/en active Active
- 2019-01-25 CN CN201910074964.3A patent/CN110090221B/zh active Active
- 2019-01-25 US US16/966,857 patent/US11510933B2/en active Active
- 2019-01-25 CN CN201910075748.0A patent/CN110090222B/zh active Active
- 2019-01-25 MX MX2020008047A patent/MX2020008047A/es unknown
- 2019-01-25 ES ES19746721T patent/ES2964618T3/es active Active
- 2019-01-25 JP JP2020542243A patent/JP7021360B2/ja active Active
- 2019-01-25 AU AU2019214081A patent/AU2019214081B2/en active Active
- 2019-01-25 WO PCT/CN2019/073239 patent/WO2019149156A1/zh active Application Filing
- 2019-01-25 BR BR112020015519-5A patent/BR112020015519A2/pt unknown
- 2019-01-25 CA CA3090025A patent/CA3090025C/en active Active
- 2019-01-25 US US16/966,855 patent/US20210038622A1/en not_active Abandoned
- 2019-01-25 AU AU2019214082A patent/AU2019214082B2/en active Active
-
2022
- 2022-05-10 US US17/662,725 patent/US11793822B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014227506A1 (en) * | 2008-12-04 | 2014-10-09 | Boehringer Ingelheim Animal Health USA Inc. | Intramammary teat sealant |
CN102234305A (zh) * | 2011-05-06 | 2011-11-09 | 南京泽朗医药科技有限公司 | 一种制备高纯度白头翁皂苷b4的方法 |
CN102898496A (zh) * | 2012-10-12 | 2013-01-30 | 苏州世林医药技术发展有限公司 | 一种齐墩果酸型皂苷的制备方法 |
CN105213410A (zh) * | 2015-10-20 | 2016-01-06 | 刘琦 | 白头翁皂苷b4作为免疫调节剂在治疗急性炎症药物中的应用 |
CN105535004A (zh) * | 2016-02-02 | 2016-05-04 | 刘琦 | 白头翁皂苷b4作为ev71病毒抑制剂在制备抗手足口病药物中的应用 |
CN107029040A (zh) * | 2017-05-02 | 2017-08-11 | 湖南农业大学 | 治疗奶牛隐性乳房炎的复方中药散剂 |
CN110090221A (zh) * | 2018-01-31 | 2019-08-06 | 四川英路维特医药科技有限公司 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
Non-Patent Citations (4)
Title |
---|
HAIFENG YANG ET AL.: "Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients", 《J VET RES》 * |
YIYI HU ET AL.: "Role of Chinese herbal medicinal ingredients in secretion of cytokines y PCV2-induced endothelial cells", 《J IMMUNOTOXICOL》 * |
宋小红等: ""白头翁汤"的作用机制及在兽医临床中的应用", 《养殖技术》 * |
李铁栓等主编: "《兽医学》", 31 May 2001, 中国农业科技出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110090221A (zh) * | 2018-01-31 | 2019-08-06 | 四川英路维特医药科技有限公司 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
CN110090221B (zh) * | 2018-01-31 | 2022-04-05 | 广西英路维特药物有限公司 | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 |
CN111249289A (zh) * | 2020-02-14 | 2020-06-09 | 广西英路维特药物有限公司 | 一种消炎和/或抗过敏的口腔护理产品或药品 |
CN113633682A (zh) * | 2021-07-22 | 2021-11-12 | 广西馨海药业科技有限公司 | 一种治疗带状疱疹的乳膏剂及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110090222A (zh) | 一种白头翁提取物在制备治疗病毒性和/或细菌性疾病的药物中的用途 | |
CN102274264B (zh) | 桔梗总皂苷在治疗和预防肺炎支原体感染性疾病药物中的应用 | |
CN101007026A (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN114404490B (zh) | 用于治疗肿瘤放化疗后白细胞减少症的中药及制备方法 | |
CN102389559A (zh) | 一种中药组合物及其作为放疗增敏剂的应用 | |
CN105878439A (zh) | 一种防治奶牛乳房炎的中药喷膜剂及其制备方法 | |
CN101721612B (zh) | 一种升高白细胞的中药组合物及其制备方法和应用 | |
CN105853618A (zh) | 一种具有广谱抗癌功效的中药组合物及其制备方法和用途 | |
CN100525816C (zh) | 一种头花蓼复方药物组合物及其制备方法和用途 | |
RU2799050C2 (ru) | Применение экстракта pulsatilla chinensis для получения лекарственного средства для лечения вирусных и/или бактериальных заболеваний | |
CN101618157B (zh) | 一种用于治疗秋燥感冒的药物组合物及其制备方法 | |
CN111544570B (zh) | 一种添加抗菌肽的抗病毒制剂及其制备方法 | |
CN102475680A (zh) | 一种盐酸千金藤素注射剂及其制法和检测方法 | |
CN107941935B (zh) | 养阴清热润肠通便用稳定的滋阴润肠口服液药物组合物 | |
CN100384444C (zh) | 治疗奶牛乳房炎的药物组合物及其制备方法 | |
CN111202789A (zh) | 以五种果蔬为原料的通便组方增加肠道水分、润滑肠道的新应用 | |
CN102716382A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN119548596A (zh) | 一种具有肺结节治疗作用的中药组合物和制备方法 | |
CN117695325A (zh) | 一种兽用玉屏风口服液及其制备方法 | |
CN116392553A (zh) | 一种治疗大肠癌转移的中药复方制剂 | |
CN117860850A (zh) | 一种改善晚期肺癌的中药组合物及制备方法 | |
CN108771708A (zh) | 一种治疗幼畜痢疾的中药组合物及其制备方法和用途 | |
CN112675218A (zh) | 一种复方胆膏注射液、制备方法及有效成分含量测定方法 | |
CN109364147A (zh) | 一种妇科千金胶囊及其制备方法 | |
CN109254098A (zh) | 一种妇科千金胶囊的质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200119 Address after: 541000 changshuiling Industrial Park, Maling Town, Lipu County, Guilin City, Guangxi Zhuang Autonomous Region Applicant after: Guangxi Yingluweite Pharmaceutical Co.,Ltd. Address before: 610000 Sichuan Chengdu high tech Zone, Tianfu Road North Section 1700, 4 1 units, 10 level 1003. Applicant before: SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of an extract of Baitouweng in the preparation of drugs for treating viral and/or bacterial diseases Granted publication date: 20220405 Pledgee: Financing Company limited by guarantee of small and micro enterprises in Guilin Pledgor: Guangxi Yingluweite Pharmaceutical Co.,Ltd. Registration number: Y2024980013432 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |